Signal active
Bio
Prior to co-founding Medicxi Ventures, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He was formerly on the board of directors of Versartis (Nasdaq: VSAR) and is currently involved with include Acutus and Levicept among others.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline).
Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.
Location
London, England, United Kingdom, Europe
Social
Primary Organization
2016
46
29
13
11-50
Venture Capital, Biotechnology, Life Science, Biopharma
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Kevin Johnson is the Co-Founder & Partner at Medicxi, based in Europe. With a background in Venture Capital, Kevin Johnson has a rich history of leadership and innovation. Kevin Johnson studied Ph.D Pathology @ University of Cambridge. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
2
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Sep 08, 2005 | PanGenetics | Seed Round - PanGenetics | Index Ventures | 2.0M |
Oct 13, 2017 | - | Series A - Impact Biomedicines | Medicxi | 22.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.